Patents Assigned to Piramal Enterprises Limited
-
Publication number: 20200289465Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.Type: ApplicationFiled: April 9, 2020Publication date: September 17, 2020Applicant: Piramal Enterprises LimitedInventors: Swati Ajay PIRAMAL, Muralidhara PADIGARU, Veena R. AGARWAL, Gandhali Ashwin DESHPANDE
-
Patent number: 10688079Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.Type: GrantFiled: September 7, 2018Date of Patent: June 23, 2020Assignee: Piramal Enterprises LimitedInventors: Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
-
Publication number: 20200185105Abstract: The present invention relates to a level meter measuring the quality health of a pharmaceutical manufacturing site and which predicts 24/7 audit readiness for quality outcomes, wherein outcome is interpreted using tangible data; referred to as a Quality Health Barometer. The present invention also relates to a method of evaluating the audit readiness of a pharmaceutical manufacturing site. The present invention further relates to a method of evaluating data integrity (DI) compliance of a pharmaceutical manufacturing site.Type: ApplicationFiled: November 27, 2019Publication date: June 11, 2020Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Rashida NAJMI, Monika BORNANI
-
Publication number: 20200138782Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.Type: ApplicationFiled: December 23, 2019Publication date: May 7, 2020Applicant: Piramal Enterprises LimitedInventors: Owe ORWAR, Sreesha SRINIVASA, Prabha MISHRA
-
Publication number: 20200123186Abstract: The present invention relates to an industrially feasible and economically viable process for preparation of Bexagliflozin of formula V in significantly high yield and purity.Type: ApplicationFiled: May 9, 2018Publication date: April 23, 2020Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Milind GHARPURE, Sanjay Kumar SHARMA, Sandesh VISHWASRAO, Prasad VICHARE, Dipak VARAL
-
Publication number: 20200046695Abstract: The present invention relates to an oral pharmaceutical composition, particularly a tablet, comprising an active ingredient lurasidone or its pharmaceutically acceptable salt(s) or solvate(s) thereof and one or more pharmaceutical excipient(s); and a process for its preparation.Type: ApplicationFiled: January 10, 2018Publication date: February 13, 2020Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Tejas SHAH, Milan B. AGRAWAL, Narendra PATEL, Devesh BHATT, Umesh BARABDE, Vipan DHALL
-
Patent number: 10555931Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.Type: GrantFiled: May 27, 2015Date of Patent: February 11, 2020Assignee: PIRAMAL ENTERPRISES LIMITEDInventors: Owe Orwar, Sreesha Srinivasa, Prabha Mishra
-
Publication number: 20190315691Abstract: The present invention provides an improved process for the preparation of N-protected ((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methanol (compound (A)) and further its transformation to Paroxetine and its pharmaceutically acceptable salts. The process comprises reaction of compound (II) with amido-malonate compound (C) in the presence of a chiral catalyst and optionally a dehydrating agent to obtain compound (B); followed by reduction of (B) in the presence of a reducing agent to provide compound (A).Type: ApplicationFiled: September 2, 2016Publication date: October 17, 2019Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Raghavendar Rao MORTHALA, Arnab ROY, Tapas MAITY, Baswaraj PATLOLLA, Murali RAJAPPA, Nilanjan MAJUMDER, Chirag PATEL, Dhileepkumar KRISHNAMURTHY, Santhosh Reddy JANGARI, Anant JAGTAP, Phani Kumar MANNEM, Pulendarreddy ARWAL
-
Patent number: 10428033Abstract: The present invention provides an improved process for preparation of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; commonly known as vortioxetine (referred to as the compound (I)) and pharmaceutically acceptable salts thereof; wherein the process comprises reaction of 2-((2,4-dimethylphenyl)thio)aniline (II) with bis(2-alkyl)amine (IIIa) or its salt in the presence of a cyclic amide solvent.Type: GrantFiled: February 14, 2018Date of Patent: October 1, 2019Assignee: Piramal Enterprises LimitedInventors: Milind Gharpure, Sanjay Kumar Sharma, Nainesh Kansagara
-
Patent number: 10428097Abstract: The present invention relates to a novel process for the preparation of intermediate of fosaprepitant dimeglumine. The present invention particularly relates to a process for the preparation of fosaprepitant dibenzyl ester, an intermediate of fosaprepitant dimeglumine, which is simple, easy to handle on commercial scale and efficient.Type: GrantFiled: November 30, 2016Date of Patent: October 1, 2019Assignee: Piramal Enterprises LimitedInventors: Milind Gharpure, Prashant Ladkat, Navnath Shinde, Ashutosh Jagtap
-
Publication number: 20190282544Abstract: The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.Type: ApplicationFiled: December 13, 2018Publication date: September 19, 2019Applicant: Piramal Enterprises LimitedInventors: Veena AGARWAL, Giridharan PERIYASAMY, Maggie RATHOS, Ankita SRIVASTAVA, Sreesha SRINIVASA
-
Patent number: 10273230Abstract: The present invention relates to substituted phenyl alkanoic acid compounds designated as the compound of Formula (I) (as described herein) or a tautomer, a stereoisomer, a geometrical isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide, a S-oxide or a carboxylic acid isostere thereof; which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of compound of Formula (I) for the treatment of diseases or disorder mediated by GPR120.Type: GrantFiled: July 23, 2015Date of Patent: April 30, 2019Assignee: Piramal Enterprises LimitedInventors: Sanjay Kumar, Rajiv Sharma, Vijaykumar Bhagwan Deore, Nilambari Nilkanth Yewalkar
-
Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck
Patent number: 10245251Abstract: The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.Type: GrantFiled: July 8, 2016Date of Patent: April 2, 2019Assignee: PIRAMAL ENTERPRISES LIMITEDInventors: Veena Agarwal, Arun Balakrishnan, Giridharan Periyasamy -
Patent number: 10227360Abstract: The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases.Type: GrantFiled: February 18, 2015Date of Patent: March 12, 2019Assignee: Piramal Enterprises LimitedInventors: Sanjay Kumar, Rajiv Sharma, Somnath Halder, Sangameshwar Prabhakar Sawargave, Vijaykumar Bhagwan Deore
-
Patent number: 10214521Abstract: The present invention relates to fused heterocyclic compound of Formula (I), a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.Type: GrantFiled: September 9, 2015Date of Patent: February 26, 2019Assignee: Piramal Enterprises LimitedInventors: Sanjay Kumar, Rajiv Sharma, Sangameshwar Prabhakar Sawargave, Vishal Mahajan
-
Patent number: 10196400Abstract: The present invention provides an improved process for preparation of the substantially pure (3aR,7aR)-4?-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1?-piperazin]-1?-ium methanesulfonate (referred to as compound-II), which is useful as a key intermediate for the synthesis of lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione). The process comprises reaction of the compound-III (as described herein) with the compound-IV (as described herein) in the presence of a solvent mixture selected from an alcohol and water; and a base The improved process for the preparation of compound II provides the product with total amount of unreacted compound-IV as impurity in less than 0.06% and the product with HPLC purity as ?99.8%. The process further refers purification of Lurasidone hydrochloride, wherein the product contains the residual acetone <5000 ppm.Type: GrantFiled: January 5, 2016Date of Patent: February 5, 2019Assignee: Piramal Enterprises LimitedInventors: Milind Gharpure, Shashi Kant Tiwari, Ganesh Wagh, Galge Revanappa, Manikrao Warpe, Yogesh Zalte, Dhileepkumar Krishnmurthy
-
Publication number: 20180369200Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.Type: ApplicationFiled: September 7, 2018Publication date: December 27, 2018Applicant: Piramal Enterprises LimitedInventors: Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
-
Publication number: 20180354977Abstract: The present invention relates to a novel process for the preparation of intermediate of fosaprepitant dimeglumine. The present invention particularly relates to a process for the preparation of fosaprepitant dibenzyl ester, an intermediate of fosaprepitant dimeglumine, which is simple, easy to handle on commercial scale and efficient.Type: ApplicationFiled: November 30, 2016Publication date: December 13, 2018Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Milind GHARPURE, Prashant LADKAT, Navnath SHINDE, Ashutosh JAGTAP
-
Patent number: 10150745Abstract: The present invention provides an improved process for the preparation of 8-chloro-1-phenyl-1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione (hereafter referred to as the compound (IV)), which is useful as a key intermediate for the synthesis of Clobazam (referred to as the compound (I)) 7-chloro-1-methyl-5-phenyl-1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione. The process of the present invention further involves transformation of the compound (IV) into Clobazam (I), comprising (a) reacting the compound (II) (as described herein) with monoalkyl malonate in the presence of a coupling agent to obtain the compound (III) (as described herein); followed by the cyclization using a base; (b) reacting the compound-IV (as described herein) obtained from step (a) with methylating agent. The process of the present invention involves formation of novel intermediates methyl 3-((4-chloro-2-(phenylamino)phenyl)amino)-3-oxopropanoate (IIIa) and 3-((4-chloro-2-(phenylamino)phenyl)amino)-3-oxopropanoic acid (V).Type: GrantFiled: March 21, 2016Date of Patent: December 11, 2018Assignee: PIRAMAL ENTERPRISES LIMITEDInventors: Ashutosh Jagtap, Milind Gharpure, Navnath Shinde, Navnath Patil, Chirag Shah, Changdev Raut, Dhileepkumar Krishnmurthy
-
Publication number: 20180344648Abstract: A pharmaceutical composition comprising clobazam or its pharmaceutically acceptable salt(s) or solvate(s) thereof of defined particle size and one or more pharmaceutically acceptable excipients is described. A method for preparing the composition is also described.Type: ApplicationFiled: November 29, 2016Publication date: December 6, 2018Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Vipan DHALL, Aravind KERUDI, Tapan BUCH, Ajay SAV